USD 1.05
(-1.87%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 8.52 Million USD | 20.97% |
2022 | 7.04 Million USD | 227.48% |
2021 | 2.15 Million USD | 3082.31% |
2020 | 67.62 Thousand USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 1.76 Million USD | -42.15% |
2024 Q2 | 1.73 Million USD | -2.12% |
2023 Q1 | 1.33 Million USD | -0.62% |
2023 Q3 | 3.16 Million USD | 225.71% |
2023 FY | 8.52 Million USD | 20.97% |
2023 Q4 | 3.05 Million USD | -3.28% |
2023 Q2 | 970.22 Thousand USD | -27.56% |
2022 Q3 | 1.8 Million USD | -25.29% |
2022 FY | 7.04 Million USD | 227.48% |
2022 Q1 | 1.47 Million USD | 0.0% |
2022 Q4 | 1.34 Million USD | -25.47% |
2022 Q2 | 2.42 Million USD | 64.54% |
2021 Q1 | 52.05 Thousand USD | 0.0% |
2021 FY | 2.15 Million USD | 3082.31% |
2020 FY | 67.62 Thousand USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Amgen Inc. | 11.87 Billion USD | 99.928% |
AstraZeneca PLC | 29.57 Billion USD | 99.971% |
Biogen Inc. | 5.2 Billion USD | 99.836% |
Gilead Sciences, Inc. | 13.01 Billion USD | 99.934% |
Scilex Holding Company | 136.49 Million USD | 93.753% |
Scilex Holding Company | 136.49 Million USD | 93.753% |